Stanza
Fibromyalgia
ApprovedActive
Key Facts
About Swing Therapeutics
Swing Therapeutics is a San Francisco-based digital health company founded in 2019, focusing on rheumatology and chronic illness management. Its core offering is Stanza, an FDA-cleared prescription digital therapeutic (PDT) for fibromyalgia, delivered via a smartphone app requiring 15 minutes of daily use. The company operates a hybrid model, offering both the Stanza therapy and the Swing Care clinic, and is backed by clinical data from randomized controlled trials demonstrating durable improvements in symptoms and quality of life. Swing is positioned in the growing digital therapeutics market, aiming to provide accessible, non-pharmacological options for chronic disease management.
View full company profileTherapeutic Areas
Other Fibromyalgia Drugs
| Drug | Company | Phase |
|---|---|---|
| SP-104 | SCILEX | Preclinical/Phase 1 |
| Sequential Dialysis Technique | Halberd | Discovery |
| Fibromyalgia Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Fibromyalgia Biomarkers | Paradise Genomics | Discovery |
| SyqeAir Inhaler – Fibromyalgia | Syqe Medical | Commercial |
| AXS-14 | Axsome Therapeutics | Phase 3 |
| SP-104 (low-dose naltrexone DR capsules) | Scilex Holding | Preclinical |